Subscribe to RSS
DOI: 10.1055/s-2001-14287
© Georg Thieme Verlag Stuttgart · New York
Clinical Use of Heparin-Coated Cardiopulmonary Bypass in Coronary Artery Bypass Grafting[*]
Publication History
Publication Date:
31 December 2001 (online)
Clinical handling, risk and benefit of a heparin-coated cardiopulmonary bypass system combined with reduced systemic heparinization in coronary bypass surgery was investigated in a prospective, randomized clinical study. 243 patients (Pts.) were divided into 3 groups: group A (n = 83) had a standard uncoated extracorporeal circulation (ECC) set, and systemic heparin was administered in an initial dose of 400 IE/kg body weight. During ECC activated clotting time (ACT) was kept ≥ 480 sec. Group B (n = 77) had the same ECC set completely coated with low-molecular-weight heparin; i. v. heparin was given in the same dose as in group A, ACT was kept at the same level. Group C (n = 83) had the same coated ECC set as group B, but i. v. heparin was reduced to 150 IE/kg, and was set to be ≥ 240 sec during ECC ACT. The same circulatory components were used in all 3 groups including roller pumps, coronary suction and an open cardiotomy reservoir. In the postoperative clinical course, recovery was not significantly different between groups, especially with respect to organ dysfunction; but there was significantly reduced postoperative bleeding where heparin-coated ECC and low-dose systemic heparinization were both used. This circulatory technique was also associated with a distinctly lower need for postoperative blood replacement. We conclude that heparin-coated extracorporeal circulation combined with either full-dose or reduced systemic heparinization can be used effectively with the same standard equipment and procedures as in uncoated technology. Combination with low-dose i. v. heparin leads to significantly decreased blood loss and less need for blood replacement.
Key words:
Cardiopulmonary bypass - Extracorporeal circulation - Heparin-coating - Low-molecular-weight heparin - Systemic heparinization - Coronary bypass surgery
1 Presented at the 3rd Joint Meeting of the German, the Austrian and the Swiss Societies for Thoracic and Cardiovascular Surgery in Lucerne on February 9 - 12, 2000
References
-
1 Edmunds L H. Jr .
Extracorporeal perfusion. In Edmunds LH Jr, ed. Cardiac surgery in the adult. New York:McGraw-Hill 1997: 255-294 - 2 Edmunds L H. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1998; 66 S 12-S 16
- 3 Borowiec J, Thelin S, Bagge L. et al . Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. J Thorac Cardiovasc Surg. 1992; 104 642-647
- 4 Øvrum E, Mollness T E, Fosse E. et al . Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. J Thorac Cardiovasc Surg . 1995; 110 1623-1632
- 5 Wendel H P, Heller W, Gallimore M J, Hoffmeister H E. Heparin coated oxygenators significantly reduce contact system activation in an in vitro cardiopulmonary bypass model. Blood Coagul Fibri-nolysis. 1994; 5 673-678
- 6 Von Segesser L K, Weiss E K, Pasic M. et al . Risk and benefit of low systemic heparinization during open heart operations. Ann Thorac Surg. 1994; 58 391-398
- 7 Øvrum E, Holen E A, Tangen G. et al . Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg. 1995; 60 365-371
- 8 Wendel H P, Heller W, Hoffmeister H E. Pathway of platelet protection in heparin-coated devices and its significance for cardiac surgery. Trans Soc Biomater. 1995; 21 281
- 9 Pekna A, Hagman L, Halden E, Nilsson U R, Nilsson B, Thelin S. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann Thorac Surg. 1994; 58 421-424
- 10 Edmunds L H. Surface bound heparin - panacea or peril?. Ann Thorac Surg. 1994; 58 285-286
- 11 Kuitunen A H, Heikkila L J, Salmenperä M T. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation. Ann Thorac Surg. 1997; 63 438-444
- 12 John L C H, Rees G M, Kovacs I B. Inhibition of platelet function by heparin. An etiologic factor in postoperative hemorrhage. J Thorac Cardiovasc Surg. 1993; 105 816-822
- 13 von Segesser L K, Weiss B M, Garcia E, Turina M I. Clinical application of heparin-coated perfusion equipment with special emphasis on patients refusing homologous transfusions. Perfusion. 1991; 6 227-233
- 14 von Segesser L K, Weiss B M, Garcia E. et al . Reduction and elimination of systemic heparinization during cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1992; 103 790-799
- 15 Butler J, Rocker G M, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 1993; 55 552-559
- 16 Gravlee G P. Heparin-coated cardiopulmonary bypass circuits. Journal of Cardiothoracic and Vascular Anesthesia. 1994; 8 (2) 213-222
-
17 Wendel H P.
Heparinbeschichtete Systeme. In: Tschaut RJ. Extrakorporale Zirkulation in Theorie und Praxis. Pabst Verlag 1999: 675-692 - 18 Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs. 1983; 11 161-173
- 19 Carr J A, Silverman N. The heparin-protamine interaction. J Cardiovasc Surg. 1999; 40 659-666
- 20 Oe M, Asou T, Morita S, Yasui H, Kouichi T. Protamine-induced hypotension in heart operations: application of the concept of ventricular-arterial coupling. J Thorac Cardiovasc Surg. 1996; 112 462-471
- 21 Ashraf S, Butler J, Tian Y, Cowan D, Lintin S, Saunders N R, Watterson K G, Martin P G. Inflammatory mediators in adults undergoing cardiopulmonary bypass: comparison of centrifugal and roller pumps. Ann Thorac Surg. 1998; 65 480-484
- 22 Wildevuur Ch R H, Jansen P G M, Bezemer P D. et al . Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European working group on heparin coated extracorporeal circulation circuits. Eur J Cardiothor Surg. 1997; 11 616-623
- 23 Libman R B, Wirkowski E, Neystat M, Barr W, Gelb S, Graver M. Stroke associated with cardiac surgery: determinants, timing and stroke subtypes. Arch Neurol. 1997; 54 83-87
- 24 Roach G W, Kanhuger M, Mangano C M. et al . Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med. 1996; 335 1857-1862
- 25 Beaufreton C, Le Besnerais P, Jansen P, Mazzucotelli J P, Widevuur C R H, Loisance D. Clinical outcome after coronary surgery with heparin-coated extracorporeal circuits for cardiopulmonary by-pass. Perfusion. 1996; 11 437-443
- 26 Wagner W R, Johnson P C, Thompson K A, Marrone G C. Heparin-coated Cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. Ann Thorac Surg. 1995; 58 734-741
- 27 Svenmarker S, Sandström E, Karlsson T, Jansson E, Häggmark S, Lindholm R, Appelblad M, Åberg T. Clinical effects of the heparin coated surface in cardiopulmonary bypass. Eur J Cardiothor Surg. 1997; 11 957-964
- 28 Aldea G S, Doursounian M, O'Gara P. et al . Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study. Ann Thorac Surg. 1996; 62 410-418
1 Presented at the 3rd Joint Meeting of the German, the Austrian and the Swiss Societies for Thoracic and Cardiovascular Surgery in Lucerne on February 9 - 12, 2000
Nikolas MirowM.D.
Department of Thoracic and Cardiovascular Surgery
Heart Center NRW
Ruhr University of Bochum
Georgstraße 11
32545 Bad Oeynhausen
Germany
Phone: +49-5731-971331
Fax: +49-5731-971300
Email: nmirow@hdz-nrw.ruhr-uni-bochum.de